Search

Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis

Kei Kato

Kei Kato, Head of Purchasing in Japan, describes a career at Boehringer Ingelheim as intense and exciting.

Being a better ally at work

We’re always identifying ways to be better allies to one another at our family-owned company.

A day of giving back at Pegasus Therapeutic Riding

Take a look at our volunteer day spent refreshing a farm committed to equine therapy.

Digital solutions save lives

Interview with Norbert Kraut: How cancer drives us forward

Norbert Kraut, our Global Head of Cancer Research at Boehringer Ingelheim, shares our approach to advancing cancer research and exploring new technologies

BI Launches Bovikalc Dry for Dairy Cows | Boehringer Ingelheim US

Click here to read more on the launch of the new Bovikalc® Dry for Dairy Cows, an oral mineral supplement contributing to well-being for dairy cows.

200 employees make a difference with record-breaking volunteer efforts

Medicine & Regulatory Video

Taimi Sahlin, a therapeutic specialist with Boehringer Ingelheim Canada describes her career as challenging and motivating.

About our Innovation Prize

Established in 2015 and jointly sponsored by BI and the BI Venture Fund, the prize allows recipients to focus on development of breakthrough medicines.

Yankees Baseball Legend Bernie Williams Raises Awareness of Devastating Lung Disease – IPF – in Honor of his Dad

Yankees Baseball Legend Bernie Williams Raises Awareness Of Devastating Lung Disease – Ipf – In Honor Of His Dad

FDA approves Gilotrif® (afatinib) in EGFR NSCLC | Boehringer Ingelheim US

FDA announces approval of a supplemental sNDA for GILOTRIF for the treatment of patients with metastatic NSCLC. View ISI, PI and Med Guide.

Real-world analysis reinforces that Gilotrif® dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy

dose adjustments reduce the frequency and intensity of adverse

Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*star for Targeted Cancer Therapies

Vienna

Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.

Dr. Hsing-Jung Chen-Engerer

Dr. Hsing-Jung Chen-Engerer of Research & Development speaks about his fulfilling career with Boehringer Ingelheim.

Karla Alvarez

Karla Alvarez speaks about her data career in Barcelona, Spain and the vibrant, international environment at Boehringer Ingelheim.

Leticia develops product medical strategies

Leticia develops product medical strategies at Boehringer Ingelheim. For more talent insights, visit our Careers Page.

Lothar Halmer

Dr. Lothar Halmer is our Chief Quality Officer, and proud to have built a 25-year career with us.

Marie Penzold

Marie Penzold talks about her career as a HR business partner in the Innovation unit here at Boehringer Ingelheim.

Alex Breiner

Alexandra Breiner, a Senior Communications Manager in Corporate Affairs, highlights her career and the many development programmes at Boehringer Ingelheim.

Shannon Rountos

Shannon Rountos, Head of Newsroom within Corporate Affairs, speaks about her rewarding and fulfilling career in Boehringer Ingelheim.

Nadine Becker

Nadine Becker, speaks about her role in the Master Data Management and her 20 year career in Boehringer Ingelheim.

Jan-Erik Schafer

Jan Erik, Senior Team Leader in the upstream pharmaceutical production talks about his motivating and fun career at Boehringer Ingelheim.

A Brave New World: Digital Health Redo | Boehringer Ingelheim US

Find out more on how digital innovation in Boehringer Ingelheim is transforming the world of animal health, including disease prevention and vaccination.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers